Research programme: Parkinson's disease therapeutics - MIGENIX/Pfizer
Latest Information Update: 30 Jan 2008
At a glance
- Originator MIGENIX
- Developer MIGENIX; Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 30 Jan 2008 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
- 15 Jun 2007 No development reported - Preclinical for Parkinson's disease in USA (unspecified route)
- 23 Sep 2004 Micrologix Biotech is now called MIGENIX